Physician profile
Michael Hackman
NPI 1013150945
$18,062.63
in general payments reported to CMS, 2019-2025
15 companies · $659 in 2025
The $659 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $180 · 2021: $1,680 · 2022: $5,520 · 2023: $9,390 · 2024: $474 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Food and Beverage: $1,849 · Travel and Lodging: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Food and Beverage | $1,849.10 |
| Travel and Lodging | $1,473.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,694.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $353.16 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $292.73 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $167.48 | 2020-2025 | Trintellix |
| Allergan, INC. | $113.00 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $102.22 | 2020-2021 | |
| Lundbeck LLC | $91.94 | 2019-2023 | Rexulti |
| Alkermes, INC. | $75.06 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.17 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $33.39 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $28.85 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $20.13 | 2025 | Fanapt |
| Novo Nordisk INC | $19.33 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $13.59 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.